Codexis, Inc. (CDXS)
After hours:
| Previous Close | 3.6500 |
| Open | 3.7300 |
| Bid | 3.6800 x 200 |
| Ask | 3.7100 x 400 |
| Day's Range | 3.6200 - 3.7550 |
| 52 Week Range | 1.4500 - 4.9100 |
| Volume | |
| Avg. Volume | 458,350 |
| Market Cap | 261.063M |
| Beta (5Y Monthly) | 2.12 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.9400 |
| Earnings Date | Aug 08, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.13 |
GlobeNewswireCodexis to Report Second Quarter 2024 Financial Results on August 8
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will host a conference call and webcast at 4:30 pm Eastern Time to discuss the Company’s financial results and provide a business update. Participants may access the live webcast on the Codexis Investor Relat
- GlobeNewswire
Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under the terms of the agreement, Codexis is eligible to receive future development and commercial milestone payments in addition to a low-to-mid single-digit percentage net sales-based royalty. “We’re thrilled to p
Simply Wall St.Investors in Codexis (NASDAQ:CDXS) have unfortunately lost 88% over the last three years
It's not possible to invest over long periods without making some bad investments. But you want to avoid the really big...
